Lutetium Lu 177 Dotatate (Lutathera)

Lutetium Lu 177 dotatate (Lutathera) takes this site's already-covered somatostatin analogs — octreotide, lanreotide, pasireotide — and turns one of them into a cancer treatment: the same peptide backbone that binds somatostatin receptors, now carrying a radioactive isotope directly into neuroendocrine tumor cells. FDA-approved in January 2018 on the strength of a genuinely dramatic Phase 3 result published in the New England Journal of Medicine, it was the first radiopharmaceutical of its kind ever approved.

A somatostatin analog carrying radiation instead of just occupying the receptor

Lutathera's active molecule is oxodotreotide — a synthetic peptide built on the same somatostatin-receptor-binding backbone as octreotide and lanreotide, already covered on this site — chelated to lutetium-177, a beta-emitting radioisotope. Where octreotide and lanreotide work by occupying the somatostatin receptor and damping down excess hormone secretion, Lutathera uses that same receptor purely as an address label: the peptide binds somatostatin receptors that neuroendocrine tumor cells overexpress, gets pulled inside the cell, and the attached lutetium-177 then irradiates the tumor from within — a mechanism called peptide receptor radionuclide therapy (PRRT). It's a genuinely different use of the same underlying biology already established by the diagnostic and symptom-control indications this site covers for octreotide and lanreotide, repurposed here to actually kill tumor cells rather than just suppress a hormone.

NETTER-1: the trial that got it approved

The pivotal NETTER-1 trial randomized 229 patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors to either Lutathera (given with a standard dose of long-acting octreotide) or high-dose octreotide alone. At the data cutoff for the primary analysis, estimated progression-free survival at 20 months was 65.2% in the Lutathera group versus 10.8% in the control group, and median progression-free survival hadn't yet been reached in the Lutathera arm versus 8.4 months in the control arm (Strosberg J, El-Haddad G, Wolin E, et al., for the NETTER-1 Trial Investigators, "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors," N Engl J Med 2017;376(2):125-135, PMID 28076709, DOI: 10.1056/NEJMoa1607427).¹ Clinically significant myelosuppression — the drug's main serious toxicity, since it circulates through bone marrow before clearing — occurred in under 10% of the Lutathera group. That result is unusually large by oncology-trial standards, and it's the basis of both the FDA's January 2018 approval and the EU's slightly earlier September 2017 authorization.

What an actual treatment cycle involves

A full course is four intravenous infusions, given roughly eight weeks apart, at a hospital or nuclear-medicine center equipped to handle radiopharmaceuticals — not an outpatient injection a clinic can offer casually. Each infusion is preceded by, and continues alongside, an amino-acid solution (a mix of L-lysine and L-arginine) given specifically to protect the kidneys, which reduces the radiation dose reaching them by roughly 47% by competing with the drug for reabsorption in the kidney tubules.² A long-acting octreotide injection is also given after each dose and continued afterward. Because the drug is genuinely radioactive, staff handle it under standard radiopharmaceutical precautions, and patients receive specific guidance on minimizing radiation exposure to others for a period after each dose — the kind of practical detail that separates this from every other peptide drug on this site, and the reason it can only be given at facilities licensed for radioactive therapeutics.

A 2024 expansion to adolescent patients

On 23 April 2024, the FDA expanded Lutathera's approval to patients 12 years and older, making it the first radiopharmaceutical approved for adolescent use in this tumor type. That expansion rested on a dedicated Phase 2 pharmacokinetic and dosimetry study (NETTER-P, NCT04711135) layered on top of the adult NETTER-1 efficacy data, rather than a new pediatric efficacy trial — the agency accepted that a pediatric patient absorbing radiation within the same organ-dose thresholds established for adults, with a comparable safety profile, could extrapolate from the adult result. It remains restricted to somatostatin-receptor-positive tumors specifically confirmed by receptor-imaging, not used empirically.

Current status

Novartis has marketed Lutathera since acquiring Advanced Accelerator Applications, the French company that originally developed and launched it, in a tender offer completed in January 2018 — essentially the same month as the US approval. It remains in active clinical use worldwide for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that express somatostatin receptors on imaging, administered exclusively through hospital nuclear-medicine departments. There is no outpatient, wellness or grey-market version of this drug in any form — a radioactive infusion requires a licensed facility by definition, not a prescription a patient could fill anywhere else.